NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

KLTO

Klotho Neurosciences Inc

Jul 01 • 04:00PM ET

1.06

Dollar change -0.07
Percentage change -6.19	%

Healthcare • Biotechnology • USA • NASD

Peers: CNC HUM MOH CI HCA UNH MCK HQY EVH GH

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.36	Insider Own	17.63%	Shs Outstand	28.51M	Perf Week	-26.39%
Market Cap	34.45M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	26.77M	Perf Month	482.42%
Enterprise Value	35.65M	PEG	-	EPS next Q	-	Inst Own	2.60%	Short Float	9.97%	Perf Quarter	365.93%
Income	-7.71M	P/S	-	EPS this Y	-	Inst Trans	-6.01%	Short Ratio	0.07	Perf Half Y	129.93%
Sales	0.00M	P/B	47.32	EPS next Y	-	ROA	-68.33%	Short Interest	2.67M	Perf YTD	118.56%
Book/sh	0.02	P/C	60.43	EPS next 5Y	-	ROE	-131.50%	52W High	3.91 -72.89%	Perf Year	-64.67%
Cash/sh	0.02	P/FCF	-	EPS past 3/5Y	-921.21% -	ROIC	-1207.48%	52W Low	0.11 833.92%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	30.09% 37.39%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-4186.52%	Oper. Margin	-	ATR (14)	0.34	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.29	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	51.30	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	0.29	EPS Q/Q	-239.75%	SMA20	-10.98%	Beta	2.57	Target Price	-
Payout	-	Debt/Eq	2.77	Sales Q/Q	-	SMA50	80.80%	Rel Volume	0.20	Prev Close	1.13
Employees	3	LT Debt/Eq	0.00	Earnings	-	SMA200	127.14%	Avg Volume	40.69M	Price	1.06
IPO	Apr 29, 2022	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	8,116,414	Change	-6.19%

Jun-30-25 02:00AM	Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS (PR Newswire) +56.92%
Jun-24-25 05:00AM	Klotho Neurosciences, Inc. and the Okinawa Research Center for Longevity Science, Leading Experts on the Okinawa "Blue Zone", Announce a Plan to Study Tissue Levels of the Human Klotho Gene and Protein in the World's Longest-Lived Population (PR Newswire) +20.00%
Jun-18-25 07:00AM	KLOTHO NEUROSCIENCES (KLTO) ANNOUNCES MUTUAL TERMINATION OF SHARE EXCHANGE AGREEMENT WITH SKYBELL TECHNOLOGIES (SKYBELL), TO CONTINUE ITS FOCUS ON THERAPEUTICS AND LONGEVITY PROGRAMS (PR Newswire)
Jun-16-25 07:00AM	KLOTHO NEUROSCIENCES RAISES OVER $11 MILLION, RETIRES ALL DEBT, AND EXCEEDS NASDAQ STOCKHOLDERS' EQUITY REQUIREMENT (PR Newswire)
Jun-09-25 07:00AM	KLOTHO NEUROSCIENCE, INC. ANNOUNCES AN APPROACH TO INCREASE LONGEVITY AND HEALTHY LIFE SPAN - REPLACE A SILENCED GENE CALLED ALPHA-KLOTHO ("a-KLOTHO") (PR Newswire) +787.80%
07:00AM	Loading…
07:00AM	KLOTHO NEUROSCIENCE, INC. ANNOUNCES AN APPROACH TO INCREASE LONGEVITY AND HEALTHY LIFE SPAN - REPLACE A SILENCED GENE CALLED ALPHA-KLOTHO ("-KLOTHO") (PR Newswire)
Jan-08-25 11:00AM	Klotho Neurosciences to Present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco (GlobeNewswire) -8.94%
Dec-09-24 11:00AM	Dr. Merit Cudkowicz, Renowned ALS Expert at Massachusetts General Hospital (MGH), Joins Klotho Neurosciences' Scientific Advisory Board (GlobeNewswire)
Dec-03-24 11:00AM	Former Merck USA President Joins Klotho Neurosciences' Board of Directors (GlobeNewswire)
Oct-23-24 06:00AM	Dr. Makoto Kuro-o, Pioneer of the Klotho Anti-Aging Gene, Joins Klotho Neurosciences, Inc. as Scientific Advisor (GlobeNewswire) -18.57%
Oct-15-24 06:00AM	Co-Founder of Shire Pharmaceuticals Appointed as Chief Operating Officer of Klotho Neurosciences (GlobeNewswire)
Sep-30-24 06:00AM	Dr. Robert Langer, Co-Founder of Moderna, Joins Scientific Advisory Board of Klotho Neurosciences, Inc. (KLTO) (GlobeNewswire) -10.95%
Sep-29-24 08:30PM	Dr. Robert Langer, Co-Founder of Moderna, Joins Scientific Advisory Board of Klotho Neurosciences, Inc. (KLTO) (GlobeNewswire)
Sep-17-24 06:30AM	ANEW MEDICAL, Inc. Announces Name Change to Klotho Neurosciences, Inc. (GlobeNewswire) +27.82%
Sep-04-24 07:46AM	Healthy Longevity is One of Key Development Goals of ANEW's Novel Gene Therapy (GlobeNewswire) -8.39%
05:00AM	Loading…
Aug-26-24 05:00AM	ANEW MEDICAL, INC. Achieves Debt-Free Status, Boosts Financial Flexibility (GlobeNewswire)
Aug-21-24 05:00AM	ANEW MEDICAL, INC. Acquires License to Needle-Free Dry Powder Autoinjector from Transfertech Sherbrooke ( TTS ) (GlobeNewswire) +15.53%
Aug-19-24 05:00AM	ANEW MEDICAL, INC. Appoints New CFO (GlobeNewswire)
Aug-15-24 05:00AM	ANEW MEDICAL, INC. Strengthens Intellectual Property Protection with U.S. Patent Issuance for Its Secreted RNA Splice Variant of the Human Klotho Gene Used for the Treatment of Neurodegenerative and Age-Related Diseases (GlobeNewswire) +11.00%
Aug-09-24 05:00AM	ANEW MEDICAL, INC. Pursues Neurological Approach to Treating Weight Loss and Eating Disorders through Melanocortin Receptor Binding Peptides (GlobeNewswire)
Aug-08-24 05:00AM	ANEW MEDICAL, INC. Announces Patents Issued in Major Asian Markets for use of Genetic Therapy in the Treatment of Alzheimer's Disease and ALS (GlobeNewswire) +17.43%
Jul-09-24 08:09AM	Why Is Anew Medical (WENA) Stock Up 51% Today? (InvestorPlace) +17.24%
07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
05:30AM	ANEW MEDICAL to Advance Patented Klotho Gene Therapy for Neurodegenerative Disorder Treatments (GlobeNewswire)
Jun-27-24 05:00AM	ANEW MEDICAL Forms Strategic Partnership with Japan's Okinawa Research Center for Longevity Science (ORCLS) to Study Klotho Gene (GlobeNewswire) -17.13%
Jun-26-24 05:00AM	ANEW MEDICAL, INC. Secures Key Patent in Europe for Human Klotho Gene RNA Slice Variant and Protein (GlobeNewswire) +119.39%

Klotho Neurosciences, Inc. engages in the provision of new therapies to treat neurodegenerative diseases. It offers cell and gene therapy. The company was founded by Joseph Sinkule on August 2, 2004 and is headquartered in Omaha, NE.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CHARDAN CAPITAL MARKETS LLC	10% Owner	Jul 02 '24	Sale	2.05	180,000	368,442	1,284,364	Jul 02 06:34 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KLTO

Klotho Neurosciences Inc

Upgrade your FINVIZ experience